AUTH/2454/11/11- Pharmacist v Celgene

Alleged promotion of Vidaza

  • Received
    07 November 2011
  • Case number
    AUTH/2454/11/11
  • Applicable Code year
    2011
  • Completed
    20 December 2011
  • No breach Clause(s)
    2, 9.1, 12.1, 18.1 and 20.1
  • Additional sanctions
  • Appeal
    No appeal
  • Review
    February 2012

Case Summary

A regional cancer hospital pharmacist complained about alleged inappropriate promotional activity by Celgene in relation to Vidaza (azacitidine). Vidaza was indicated for the treatment of certain adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) or acute myeloid leukaemia (AML).

The complainant stated that he was invited at the time of the submission of azacitidine to the Scottish Medicines Consortium (SMC) (around about August 2011) to attend an advisory panel meeting. Payment was to include travel plus a £600 honorarium. The meeting was to take place after the submission to the SMC and the complainant was aware that other pharmacists were also approached. Just before the British Oncology Pharmacy Association (BOPA) conference, the complainant was invited to another meeting for senior regional pharmacists post-SMC, again with a £600 honorarium. The complainant was aware that two local haematologists were also approached and they had suggested that events took place with quite a number of doctors. In September/October the local haematology pharmacist was invited to participate in an advisory panel and offered a £600 honorarium. The complainant was concerned about the advisory element of the meeting. The complainant had not been to any of the meetings but an agenda he had seen did not seem to form the requirements for a genuine review panel.

The detailed response from Celgene is given below.

The Panel noted from Celgene's submission that there was only one advisory board meeting held in relation to the use of Vidaza in Scotland. The date of the meeting had been changed and thus two invitations had been sent. The meeting was held in November and attended by four clinicians, one pharmacist and three Celgene employees. The complainant did not attend the meeting. The Panel noted that the health professional invitees were selected based on their interest and work in the area of MDS.

The Panel noted that the invitation to the advisory board meeting was clear that the meeting was an advisory board and the objectives were stated. Background information for the attendees asked them to review the information provided and questions posed so as to facilitate open, in-depth discussion. The chairman was briefed to, inter alia, 'help drive informative and useful discussions around the provided topics'.The Panel considered that the fee of £600 offered to attendees reflected the time spent preparing for the meeting and expected participation on the day. The Panel considered that the invitation should have referred to the preparation work required by attendees.

The Panel noted that the advisory board meeting that took place in October was not related to Vidaza. The organisation of the meeting appeared to be similar to that of the Vidaza advisory board.

The Panel did not consider that the Vidaza advisory board meeting, the arrangements or the documentation constituted disguised promotion of Vidaza. The Panel considered that the attendees were engaged as genuine consultants; there appeared to be a legitimate need for their services, the number engaged was not unreasonable to achieve the identified objectives and the payment appeared reasonable. No breach was ruled. The Panel considered that as the payment offered to attendees reflected the services provided by each it was not a pecuniary advantage offered as an inducement to prescribe. No breaches of the Code were ruled including Clause 2.